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ess: mcazzola@qubisoftSummary Sixty-five consecutive eligible adult patients, who were treated as
outpatients for stable severe-to-very severe COPD, were enrolled in the study. All of
them received 23-valent pneumococcal capsular polysaccharide vaccine intramus-
cularly. Patients were seen monthly, as well as whenever they had symptoms
suggestive of an exacerbation, at our outpatient clinic. Eighteen out of 65 patients
suffered from acute exacerbation (AECOPD). Three of these patients presented two
episodes of AECOPD. Patients with an acute exacerbation of COPD received
azithromycin 500mg/day once daily for 3 days and a short course of oral
prednisolone 25mg/die. In 16 cases, a single species was isolated, while in the
remaining 5 cases at least two species were recovered. Clinical cure or improvement
at the end of therapy (3–5 days post-therapy) was reported in 17 episodes of AECOPD
with no relapse at the late post-therapy (10–14 days after the completion of
treatment). Bacteriologic eradication or presumptive eradication rates at the end of
therapy were 86% (24 out of 28 isolates). Azithromycin eradicated all isolates of
Haemophilus influenzae, Moraxella catarrhalis, H. parainfluenzae, Klebsiella
pneumoniae, and Klebsiella spp. isolated at baseline. Eradication of Sta aureus
occurred in 1 of 3 isolates whereas azithromycin was unable to eradicate
Pseudomonas aeruginosa isolates. Our data seem to indicate that pneumococcal
vaccination reduces the possibility that an AECOPD is caused by Streptococcus
pneumoniae. This finding allows the use of antibiotics such as azithromycin, which,
otherwise, should be avoided because of resistances.
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Resistance to macrolides in strains of Streptococcus
pneumoniae varies markedly in different parts of
the world. This variability is illustrated in the range
of macrolide resistance in Europe, where over 40%
of isolates from France and Italy were resistant, in
contrast to less than 10% of isolates from Germany,
The Netherlands, the Czech Republic and Poland.1
Poor activity of macrolides in vitro is hypothetically
reflected in a poor clinical response. There are now
several reports of failure when using a macrolide to
treat a pneumococcal infection caused by a macro-
lide-resistant strain.2–7 Recently, Lonks et al.7 used a
matched case-controlled study to investigate
whether breakthrough bacteraemia (defined as
pneumococcal bacteraemia occurring in patients
receiving macrolide therapy) was linked with the
susceptibility of the isolate to macrolides. In 136
control patients infected with erythromycin-suscep-
tible pneumococci, there was no evidence of break-
through bacteraemia, but it occurred in 24% (18/76)
of patients infected with strains of reduced suscept-
ibility to erythromycin, including intermediate and
resistant cases.7 However, the mortality rate tended
to be lower among case patients taking macrolides
than among patients not taking a macrolide (0%
versus 18%; P ¼ 0:06), which is an intriguing finding.7
The estimated increased prevalence of macrolide
and multidrug resistant pneumococci worldwide
might reduce the efficacy of macrolides to treat
pneumococcal lower respiratory tract infections.8
The problem of resistance is heightened by the
difficulty in choice among commonly used groups of
antibiotics, since resistance to erythromycin is
prevalent among penicillin-resistant strains9 and
resistance to ciprofloxacin is prevalent among
penicillin-non-susceptible and erythromycin-resis-
tant strains.9,10
Antibiotic resistance has presented a new clinical
challenge especially for the treatment of pneumo-
coccal lower respiratory tract infections. It has also
revived interest in the prevention of pneumococcal
infections by vaccination, raising the question of
whether more extensive use of the present vaccine
would be an effective means for the prevention and
control of antibiotic-resistant pneumococcal dis-
ease. Today, 23-valent pneumococcal polysacchar-
ide vaccines, covering the 23 most important of the
90 pneumococcal serotypes, are available through-
out the world and used to a variable extent in high-
risk groups and the elderly.
S. pneumoniae is a pathogen commonly asso-
ciated with acute bacterial exacerbations of
obstructive pulmonary disease (AECOPD). Among
patients with AECOPD, it is estimated to beresponsible for 15–25%.11 Despite reports of macro-
lide-resistant S. pneumoniae, advanced-generation
macrolides, azithromycin and clarithromycin are
still commonly used in the empirical treatment of
AECOPD.12 In fact, as evidenced by the study of
Destache et al.13 these macrolide agents provide a
broader spectrum of activity than did the older
generic agents and improve outcomes in patients
with AECB of bacterial origin.
Because the choice of initial therapy in the
treatment of community-acquired respiratory in-
fections is empirical (i.e. made without the benefit
of knowing the pathogen and its antibiotic suscept-
ibility) due to the fact that office-based physicians
can rarely, if ever, obtain sputum samples with
which to identify causal pathogens,14 and in view of
the increasing prevalence of macrolide-resistant
pneumococci, we evaluated the clinical and bac-
teriologic outcomes associated with using a stan-
dard 3-day course of oral azithromycin for the
outpatient treatment of those patients with
AECOPD who had received 23-valent pneumococcal
polysaccharide vaccine.Patients and methods
Sixty-five consecutive eligible adult patients, who
were treated as outpatients for stable severe-to-very
severe COPD in accordance with American Thoracic
Society/European Respiratory Society criteria,15
were enrolled in the study. Table 1 shows the
baseline demographics and characteristics of the
enrolled patients. All patients were treated with
salmeterol/fluticasone 50=250mg combination bid
and continued to take the possible usual therapies
for concomitant co-pathologies. All of them received
23-valent pneumococcal capsular polysaccharide
vaccine 0.5mL (25mg each capsular type) intramus-
cularly. We excluded from the study immunocom-
promised people with presumed poor response to the
vaccine (such as patients with myeloma or other
active malignant disease, renal dialysis, hypogam-
maglobulinaemia, anatomical or functional asplenia,
or HIV-1 infection).16 Written informed consent was
obtained before patient enrolment.
The inclusion period was from September 1 to
December 31, 2003. The follow-up period ended on
July 31, 2004. Patients were seen monthly, as well
as whenever they had symptoms suggestive of an
exacerbation, at our outpatient clinic.
At each of these visits, clinical information and
sputum, when present, and serum samples were
obtained. Patients were questioned about the
status of their chronic respiratory symptoms
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Table 1 Baseline demographics and characteris-
tics of the enrolled patients.
Variable Number (%)
of patients
Sex
Male 51 (78)
Female 14 (22)
Age (years) 62.4712.8
FEV1
p50% of normal 42 (65)
430% of normal 23 (35)
Co-existing cardiopulmonary
disease
Yes 31 (48)
No 34 (52)
Exacerbations in previous year
X3 18 (28)
o3 47 (72)
Smoking
Yes 53 (81)
No 12 (19)
Treatment of AECOPD 665(dyspnea, cough, sputum production, viscosity, and
purulence), and the responses were graded as 1 (at
the usual level), 2 (somewhat worse than usual), or
3 (much worse than usual) according to the method
of Sethi et al.17 A minor worsening of two or more
symptoms or a major worsening of one or more
symptoms prompted a clinical assessment of the
cause.17 If the patient had fever (a temperature
that exceeded 38.0 1C), appeared ill, or had signs of
consolidation on examination of the lungs, a chest
film was obtained to rule out pneumonia. If other
causes of the worsening of symptoms, such as
pneumonia, upper respiratory infection, and con-
gestive heart failure, were ruled out, the patient
was considered to be having an AECOPD. All
patients produced a sputum specimen. Those
specimens that contained 425 neutrophils and
p10 epithelial cells per low-power (100 ) micro-
scopical field were submitted for culture. The
determination of whether the patient had stable
disease or an exacerbation was made before the
results of sputum cultures were available.
All patients with an AECOPD received azithromy-
cin 500mg/day once daily for 3 days and a short
course of oral prednisolone 25mg/die.
To compare the efficacy of the antibiotic treat-
ment, clinical and bacteriological responses were
assessed 3–5 (post-therapy) and 10–14 (late post-
therapy) days after the completion of treatment.
Clinical (symptomatic) response was assessed by
the investigators as follows: cure: an elimination ofsigns and symptoms and no recurrence at the
follow-up visits; improvement: a significant, but
incomplete, resolution of signs or symptoms;
relapse: worsening of signs and symptoms following
an initial improvement; failure: no improvement.
Patients were designated as unappreciable if they
could not be assigned to a category and were
disqualified for efficacy analysis.
Patients were classified as bacteriologically
appraisable if they had a positive culture of a
pre-therapy sputum specimen with a respiratory
pathogen. The following organisms were consid-
ered potential pathogens: Haemophilus influenzae,
Klebsiella pneumoniae, S. pneumoniae, Klebsiella
spp., Moraxella catarrhalis, Staphylococcus aur-
eus, H. parainfluenzae and Pseudomonas aerugino-
sa. At post-therapy, bacteriological response was
based on microbiological culture data as follows:
eradication: pathogen eliminated; persistence:
culture positive for original pathogen; colonization:
culture positive for a new pathogen without the
signs of infection; superinfection: culture positive
for a new pathogen during therapy (required
symptomatic response). At late post therapy visit,
it was based as follows: eradication: pathogen
eliminated; relapse: recurrence of the same patho-
gen with or without the development of resistance
(required a positive follow-up culture preceded by
at least one negative culture); colonization: cul-
ture positive for a new pathogen without the signs
of infection; eradication with reinfection: culture
positive for a new pathogen after treatment
(required symptomatic response of failure or
relapse). If no follow-up sputum specimen was
produced for culture, the following definitions
were assigned: presumed microbiological persis-
tence: no follow-up culture obtained with a
symptomatic response of relapse or failure; pre-
sumptive eradication: implied absence of appro-
priate material for culture, or culture not clinically
indicated (required symptomatic response of cure
or improvement); indeterminate: could not be
evaluated (bacteriological response could not be
defined or categorized), or new antibiotic started
for a condition other than the study indication
before appropriate material for culture was ob-
tained, or no pathogen isolated from the pre-
therapy culture.Results
Eighteen out of 65 patients suffered from AECOPD.
Three of these patients presented two episodes of
AECOPD.
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Table 4 Bacteriological results in isolates of
patients with acute exacerbation of COPD.
Bacteriological response Number (%)
of isolates
Post-therapy
Isolate number 28 (1 0 0)
Eradication or presumptive
eradication
24 (86)
Persistence or presumed
persistence
4 (14)
Colonization 0 (0)
Superinfection 0 (0)
Indeterminate 0 (0)
Late post-therapy
Isolate number 24 (1 0 0)
Eradication or presumptive
eradication
24 (1 0 0)
Relapse 0 (0)
Colonization 0 (0)
Eradication with reinfection 0 (0)
Indeterminate 0 (0)
M. Cazzola et al.666In 16 cases, a single species was isolated, while in
the remaining 5 cases at least two species were
recovered, with a total of 28 bacterial isolates
obtained at baseline (Table 2). The species isolated
were H. influenzae (9 isolates), M. catarrhalis
(5 isolates), H. parainfluenzae (5 isolates), K.
pneumoniae (3 isolates), S. aureus (3 isolates), P.
aeruginosa (2 isolates), Klebsiella spp. (1 isolates).
No S. pneumoniae strain was isolated from the
sputum of our patients.
Clinical cure or improvement at the end of
therapy (3–5 days post-therapy) was reported in
17 out of 21 episodes of AECOPD, with no relapse at
the late post-therapy (10–14 days after the
completion of treatment) (Table 3).
Bacteriologic eradication or presumptive eradi-
cation rates at post-therapy were 86% (24 out of 28
isolates) (Table 4). Azithromycin eradicated all
isolates of H. influenzae, M. catarrhalis, H. para-
influenzae, K. pneumoniae, and Klebsiella spp.
isolated at baseline. Eradication of S. aureus
occurred in 1 of 3 isolates whereas azithromycin
was unable to eradicate P. aeruginosa isolates. AtTable 2 Pathogens isolated prior to treatment
(n ¼ 28) in 21 episodes of acute exacerbation of
COPD.
H. influenzae 9
M. catarrhalis 5
S. aureus 3
H. parainfluenzae 5
K. pneumoniae 3
P. aeruginosa 2
Klebsiella spp 1
Table 3 Clinical responses in patients with acute
exacerbation of COPD.
Clinical response Number (%) of patients
Post-therapy
Patient number 21 (1 0 0)
Cure 11 (52)
Improvement 6 (29)
Relapse 0 (0)
Failure 4 (19)
Unappreciable 0 (0)
Late post-therapy
Patient number 17 (1 0 0)
Cure 17 (1 0 0)
Improvement 0 (0)
Relapse 0 (0)
Failure 0 (0)
Unappreciable 0 (0)the late post-therapy, neither relapse nor reinfec-
tion was observed.Discussion
Recent documentation has shown that airway
colonization with S. pneumoniae, specifically when
present as a monoculture, increases the risk of a
first COPD exacerbation.18 Also Sethi et al.17
showed a significant increase in exacerbations
when S. pneumoniae was isolated. It is clear,
therefore, that the dilemma facing the clinician
who must initiate therapy before culture
results are available is that treatment of AECOPD
must cover S. pneumoniae, which is becoming
increasingly resistant to ß-lactam and macrolide
antibacterials.1 The situation is compounded by
cross-resistance within and between classes of
antibacterial agents, which further limits treat-
ment options.
The ultimate tool of modern medicine for
combating infectious diseases may be the vaccine.
COPD patients are able to mount a significant
immune response to pneumococcal infection. They
may therefore benefit from pneumococcal vaccina-
tion.18 The modern pneumococcal vaccine was
introduced in 1977, and expanded from 14 to 23-
valent in 1983 to include between 75% and 90% of
all pathogenic strains associated with bacterae-
mia.19 The polysaccharide vaccine has not only
been shown to be highly effective, but also safe,
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Treatment of AECOPD 667and cost effective.16,20 A retrospective study,
which involved 1898 patients with chronic lung
disease documented that receipt of pneumococcal
vaccine, as defined by administrative data, was
associated with significant reductions in the risk of
hospitalization for pneumonia and influenza.21
Nonetheless, it has been suggested that the overall
efficacy of the vaccine is possibly reduced in elderly
patients with COPD.22 Leech et al.23 did not
observe significantly difference in the rates of
death, hospital admissions and emergency visits
and the mean length of hospital over a 2-year
period between a group of patients who received
the 14-valent pneumococcal vaccine and another
treated with saline placebo. However, David et
al.24 who assessed the importance of S. pneumo-
niae and immunologic response to 14-valent pneu-
mococcal vaccine in a randomized (saline placebo
or vaccine) double-blind study involving patients
with COPD, documented that although pneumonia
occurred frequently in these patients, non-pneu-
mococcal causes predominated and isolates from
sputum were predominantly non-vaccine types.
Recently, Bogaert et al.18 have shown that pneu-
mococcal colonization in COPD patients is fre-
quently caused by vaccine serotype strains.
However, mathematical modelling and animal data
suggest that serotype replacement may occur after
the initiation of routine vaccination pro-
grammes,25–27 which may question the overall
effectiveness of pneumococcal vaccination.
In the present study, only 18 out of 65 patients
vaccinated against S. pneumoniae suffered from an
AECOPD, but none of them had an episode caused
by S. pneumoniae. This a surprising finding con-
sidering the amount of acute exacerbations that
patients suffered from in the previous year. We
cannot define the exact value of 23-valent pneu-
mococcal polysaccharide vaccine because this was
not a placebo controlled study. We must stress,
however, that all patients were under regular
treatment with salmeterol/fluticasone combina-
tion, and it is well known that this treatment
reduces the number of AECOPD episodes.28 It has
been suggested that fluticasone propionate and
salmeterol could augment antibiotic treatment by
maintaining epithelial integrity and reducing the
number of sites available for bacterial adher-
ence.29 Bacteria adherent to mucus are cleared
via the mucociliary system, which would be
enhanced by the preservation of ciliated cells.
Salmeterol and fluticasone when administered
together at low concentrations, exhibit a synergis-
tic effect with respect to the preservation of
ciliated cells, showing a trend toward reduced
damage and a significant preservation of thenumber of ciliated cells compared to either agent
alone at the same concentrations.29 It seems
important to highlight that the use of salmeterol/
fluticasone combination for treating COPD
patients was permitted in Italy only after the first
months of 2003 and, for this reason, 48 patients
received it for the first time only after the
enrolment in the study. However, other factors
could justify this finding. For example, the period
of observation varied between 7 and 10.5 months,
that was always less than 1 year. One way of partly
overcomes the lack of the placebo arm is to refer to
the same period the year before and list the
number of exacerbations during that period but,
unfortunately, we only asked for the number of
exacerbations that patients had suffered in the
previous year. We must also highlight that between
June and August 2003 there was a heat wave
that has influenced the levels of pollution;
consequently, it can partially justify the number
of AECOPD suffered from our patients in the
previous year.
We did not measure the antibody response of
patients to vaccine, and this is a bias of our study,
considering that it has been documented that the
majority of individuals respond to the vaccinations
with a marked increase in antibody levels, but
there are individuals who do not respond, demon-
strating the individual variability in the response to
vaccination with these antigens.30 The small
studied sample and the lack of a placebo arm are
other two important biases, but this was a single-
centre, non-sponsored study that wished to repeat
what happens in the real daily life.
In any case, our data seem to indicate that
pneumococcal vaccination reduces the possibility
that an AECOPD is caused by S. pneumoniae. This
finding was not really unexpected, but we must
highlight that all the enrolled patients were
suffering from severe-to-very severe COPD and it
has been documented that in patients with
FEV1o50%, S. pneumoniae is isolated with less
frequency than H. influenzae, Enterobacteriaceae
and Pseudomonas species.31,32 All our patients
were immunocompetent and a recent meta-analy-
sis has documented unambiguously the high effi-
cacy of pneumococcal polysaccharide vaccine in
reducing definite pneumococcal pneumonia by 71%
in immunocompetent adults.33 This finding allows
the use of antibiotics such as azithromycin, which,
otherwise, should be avoided because of resis-
tances. In effect, as a result of the in vitro reports,
many prescribers are changing their choice of
antibiotics for pneumococcal, as well as for
community-acquired respiratory tract infections in
general, away from macrolides.
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M. Cazzola et al.668Although, according to our data, we consider
pneumococcal vaccination an important therapeu-
tic action in COPD patients, we cannot omit to
highlight that we have treated our patients with
azithromycin when they were suffering from an
acute exacerbation. The activity of this azalide
against common respiratory pathogens remains
satisfying, although its reduced in vitro activity
against macrolide-resistant S. pneumoniae.34 Our
data seem to indicate that azithromycin is a good
choice for treating acute exacerbations in COPD
patients vaccinated against S. pneumoniae. The
small sample of treated patients and the reduced
number of AECOPD that these patients have
suffered from, however, do not allow us to draw
solid conclusions. In any case, despite increasing
concerns over macrolide resistance and a higher
incidence of Gram-negative pathogens, a standard
5-day course of oral azithromycin was clinically and
bacteriologically equivalent to a 7-day course of
oral levofloxacin in the treatment of patients with
acute bacterial exacerbations of chronic bronchitis
that were not vaccinated against S. pneumoniae.35
This result is not surprising because, although
azithromycin is mainly located intracellularly, the
clinically achievable concentration of this macro-
lide in epithelial lining fluid (ELF), which has been
suggested to be more predictive of the potential
antimicrobial effects of azithromycin against ex-
tracellular pathogens associated with lower re-
spiratory tract infections,36 exceed the MIC90s of
the common respiratory pathogens included macro-
lide-susceptible S. pneumoniae but not macrolide-
resistant S. pneumoniae.37 It has been calculated
that for an MIC of 0.5 mg/mL1, after administra-
tion of azithromycin 500mg on day 1 and 250mg
daily for the next 4 days to a 70 kg subject,
AUC024/MIC, which has been suggested to be the
most predictive pharmacodynamic parameter for
the efficacy of azithromycin, is 57.5 for ELF.38 A
plasma AUC0–24/MIC ratio of at least 10 (non-
neutropenic host) and 25–30 (neutropenic host)
have been suggested for the in vivo bacteriologic
response of the common respiratory pathogens.37
It must be highlight that because of high tissue
bioavailability, azithromycin has better in vivo
efficacy than comparative agents, despite a similar
or higher MIC. In particular, the reason for the
disparity between the rates of in vitro resistance
and clinical failures has been hypothesized to be
due to high concentrations of the drug within the
WBCs (peak intracellular azithromycin concentra-
tions within phagocytic cells reach at least 80mg/L
and these concentrations are still 20–40mg/L 12
days later) that bacteria are exposed to on
phagocytosis, both in the blood and at the infectionsite.39 As it is the phagocytes that take up and clear
the bacteria from the infection site or the blood,
Amsden40 has suggested that azithromycin’s phar-
macokinetics should enable the drug to be effective
in an infection, even with resistant pneumococci,
as long as the MICs do not rise much above
16–32mg/L. These values could be used as the
breakpoint, whether the dynamics of azithromycin
are dependent on maximizing the AUC above the
MIC or the time above MIC. It is likely that by
choosing clinical MIC breakpoints of 4–8mg/L for
azithromycin rather than the present standard
breakpoints of X2mg/L, the clinician can make a
choice that will optimize the pharmacodynamics of
the drug against the isolated pathogen and result in
the best possible clinical outcome.
Considering the high level of macrolide-resis-
tance in S. pneumoniae in Italy, we believe the
results of the present study suggest an interesting
therapeutic possibility that, in any case, must be
explored with a larger, better designed trial. In
particular, a study must be designed that will
compare the impact of azithromycin and a classic
macrolide, such as clarithromycin or roxithromycin,
in the treatment of acute exacerbations in COPD
patients vaccinated against S. pneumoniae in order
to confirm the advantage of this azalide over the
other macrolides.References
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